Regeneron Beats Quarterly Estimates on Eczema Drug Strength, Shares Rise

How Telix landed a $2.1 billion radiopharma deal with Regeneron

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.

Regeneron beats quarterly estimates on eczema drug strength, shares rise

Regeneron Reports Second Quarter 2026 Financial and Operating Results

Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025Dupixent® global net sales(recorded by Sanofi) increased 38% to a new all-time high of $6.0...

REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion. Its non-GAAP profit of $14.29 per share was 40.1% above analysts' consensus estimates. Is now the time to buy REGN? Find out in our full…

Regeneron Reports Second Quarter 2026 Financial and Operating Results - PressReach

Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion EYLEA HD® U.S. net sales increased 52% to a new all-time high of $596 million Libtayo® global net sales increased 30% to a new all-time high of $489 million GAAP EPS of $12.23, including $1.02 negative impact from IPR&D; non-GAAP EPS(a) of $14.29, including $0.9…